

1 **A critical time window for recovery extends** 2 **beyond one-year post-stroke**

Belén Rubio Ballester¹, Martina Maier¹, Armin Duff¹, Mónica Cameirão²,
Sergi Bermúdez², Esther Duarte³, Ampar Cuxart⁴, Susana Rodríguez⁴,
Rosa María San Segundo Mozo⁵, and Paul F.M.J. Verschure^{1,6,*}

¹Laboratory of Synthetic Perceptive, Emotive and Cognitive Systems, Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain.

3 ²Madeira Interactive Technologies Institute and Universidade da Madeira, Campus universitário da Penteada, Funchal, Portugal.

³Servei de Medicina Física i Rehabilitació, Hospitals del Mar i l'Esperança, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.

⁴Servei de Medicina Física i Rehabilitació, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

⁵Servei de Medicina Física i Rehabilitació, Hospital Joan XIII, Tarragona, Spain.

⁶ICREA, Institució Catalana de Recerca i Estudis Avançats, Passeig Lluís Companys, Barcelona, Spain.

*Corresponding author: brubio@ibecbarcelona.eu (Belén Rubio Ballester)

4 **Abstract**

5 The impact of rehabilitation on post-stroke motor recovery and its dependency on
6 the patient's chronicity remain unclear. The field has widely accepted the notion of a
7 proportional recovery rule with a 'critical window for recovery' within the first 3-6 months
8 post-stroke. This hypothesis justifies the general cessation of physical therapy at chronic
9 stages. However, the limits of this critical window have, so far, been poorly defined. In this
10 analysis, we address this question, and we further explore the temporal structure of motor
11 recovery using individual patient data from a homogeneous sample of 219 individuals
12 with mild to moderate upper-limb hemiparesis. We observed that improvement in body
13 function and structure was possible even at late chronic stages. A bootstrapping analysis
14 revealed a gradient of enhanced sensitivity to treatment that extended beyond 12 months
15 post-stroke. Clinical guidelines for rehabilitation should be revised in the context of this
16 temporal structure.

17 **Key words**

18 Neuroplasticity, Stroke Recovery, Neurorehabilitation, Virtual Reality, Motor Recovery

19 **New and Noteworthy**

20 Previous studies on humans suggest that there is a 3-6 months 'critical window' of height-
21 ened neuroplasticity post-stroke. We analyze the temporal structure of recovery in patients
22 with hemiparesis and uncover a precise gradient of enhanced sensitivity to treatment that
23 expands far beyond the limits of the so-called 'critical window'. These findings highlight
24 the need for providing therapy to patients at the chronic and late chronic stages.

25 **Introduction**

26 The absolute incidence of stroke will continue to rise globally with a predicted 12 million
27 stroke deaths in 2030 and 60 million stroke survivors worldwide (15). Stroke leads to focal
28 lesions in the brain due to cell death following hypoxia and inflammation, affecting both
29 gray and white matter tracts (8). After a stroke, a wide range of deficits can occur with
30 varying onset latencies such as hemiparesis, abnormal posture, spatial hemineglect, aphasia,
31 and spasticity, along with affective and cognitive deficits, chronic pain and depression (34).
32 Due to improved treatment procedures during the acute stage of stroke (e.g. thrombolysis
33 and thrombectomy), the associated reduction in stroke mortality has led to a greater
34 proportion of patients facing impairments and needing long-term care and rehabilitation.
35 However, prevention, diagnostics, rehabilitation and prognostics of stroke recovery have
36 not kept pace (35).

37 Motor recovery after stroke has been widely operationalized as the individual's change
38 in two domains: 1) body function and structure (38), whose improvement has been called
39 "true recovery" (5) and refers to the restitution of a movement repertoire that the individual
40 had before the injury, and 2) the ability to successfully perform the activities of daily living
41 (24). While the former is mainly due to the interaction of post-stroke plasticity mechanisms
42 and sensorimotor training, the latter is also influenced by the use of explicit and implicit
43 compensatory strategies (5, 22). The most accepted measure for recovery of body function
44 and structure is the change in UE-FM scores (Kwakkel et al., 2017), while other clinical
45 scales focus on the assessment of activities, such as the Chedoke Arm and Hand Activity
46 Inventory (CAHAI) (3) or the Barthel Index for Activities of Daily Living (BI) (16).

47 Post-stroke motor recovery mostly follows a non-linear trajectory that reaches asymp-
48 totic levels a few months after the injury (21). This model suggests the existence of a period
49 of heightened plasticity in which the patient seems to be more responsive to treatment, the
50 so-called 'critical window' for recovery. Aiming at characterizing the temporal structure of
51 recovery, animal models and clinical research have identified a combination of mechanisms
52 underlying neurological repair that seems to be unique to the injured brain, including neu-
53 rogenesis, gliogenesis, axonal sprouting, and the rebalancing of excitation and inhibition in
54 cortical networks (36). This state of enhanced plasticity seems to be transient and interacts
55 closely with sensorimotor training to facilitate the recovery of motor function (40). How-
56 ever, there is no clear evidence of the exact temporal structure of enhanced responsiveness
57 to treatment in humans, and as a result, the optimal timing and intensity of treatment remain
58 unclear. A systematic review of 14 studies suggested that, in average, recovery reaches
59 plateau at 15 weeks post-stroke for patients with severe hemiparesis and at 6.5 weeks for
60 patients with mild hemiparesis (17). This study however failed to conduct a meta-analysis
61 due to substantial heterogeneity of the sample and protocols. Currently, an ongoing clinical

62 trial is investigating the existence and the duration of a 'critical window' of enhanced
63 neuroplasticity in humans following ischaemic stroke (27). Based on the assumption of
64 the existence of this critical period, the SMARTS 2 trial (NCT02292251)(20) is currently
65 investigating the effect of early and intensive therapy on upper extremity motor recovery.
66 Sharing the same research question, the Critical Periods After Stroke Study (CPASS) is a
67 large ongoing randomized controlled trial that focuses on determining the optimal time
68 after stroke for intensive motor training (10). To contribute to the delineation of a temporal
69 structure of stroke recovery in humans, we perform an analysis of individual patient clinical
70 data from 219 subjects with upper-limb hemiparesis, who followed occupational therapy
71 (OT) or a VR-based training protocol using the Rehabilitation Gaming System (RGS) (7)
72 (Figure S1 in Supplementary Material [DOI: 10.5281/zenodo.2611949]). We show that
73 physical therapy has a significant impact on the function of the upper extremity (UE) at all
74 periods post-stroke considered, uncovering a gradient of responsiveness to treatment that
75 extends more than 12 months post-stroke.

76 **Materials and Methods**

77 **Data Sets**

78 In this analysis, we included individual patient data from a set of protocols for the re-
79 covery of upper extremity function. These protocols included interventions combining
80 occupational therapy (OT) and a specific VR training protocol (RGS) (Section 1 in Sup-
81 plementary Material [DOI: 10.5281/zenodo.2611949]). Participants met the following
82 inclusion criteria: 1) ischemic strokes (Middle cerebral artery territory) or hemorrhagic
83 strokes (intracerebral), 2) mild-to-moderate upper limb hemiparesis (Medical Research
84 Council scale for proximal muscles > 2) after a first-ever stroke, 3) age between 45 and
85 85 years old, 4) the absence of any significant cognitive impairment (Mini-Mental State
86 Evaluation > 22). All research on human subjects reported in this manuscript was prospec-
87 tively approved by the Institutional Review Board of Hospital Joan XXIII, Hospital Vall
88 d'Hebron and Hospital del Mar i l'Esperança from Catalonia, and all participants provided
89 written informed consent.

90 The datasets were divided into 17 conditions depending on the specific characteristics
91 of the patients and the requirements of the treatment provided (Table 1). Most of the RGS
92 conditions included in this analysis have an identical design based on the same set of
93 neurorehabilitation principles (25) (see Supplementary Material for a full description of
94 the system and its mechanisms [DOI: 10.5281/zenodo.2611949]). However, two relevant
95 design differences should be noticed. First, in four protocols used with acute patients the
96 dosage was three days a week instead of five (conditions 2, 4, 5, and 6, in Table 1). Second,
97 in one study the implicit feedback is augmented through haptic actuators (condition 14 in
98 Table 1, RGS Haptics).

99 Furthermore, all RGS protocols used by acute and subacute patients, combined RGS-
100 based training with supervised OT, while condition 13 tested the application of RGS in a
101 domiciliary setting. Despite these differences, in all RGS conditions the same protocol was
102 used. A formal risk of bias analysis on the primary outcome (i.e., change in the Fugl-Meyer
103 Assessment of the upper extremity) was performed using ROBINS-I tool (Table S1 in
104 Supplementary Material [DOI: 10.5281/zenodo.2611949.]), covering the evaluation of

Table 1. Overview of the therapy conditions.

ID	Group	Average Chronicity	Intervention	N	Age Mean(SD)	TSO (days)	HA (%left)	Sex (%male)	Oxf.Class.	Reference
1	Control	Acute	12w;5d/w;20min;	5	69(19)	9(15)	40	80	2/1/0/1/1	(12)
2	RGS	Acute	3w;5d/w;20min;	5	70(22)	11(4)	60	20	1/2/0/1/1	(12, 32)
3	RGS	Acute	12w;3d/w;20min;	10	63.5(29)	11(17)	40	30	2/2/2/3/1	(9, 12)
4	Control	Acute	3w;5d/w;20min;	5	64(16)	13(5)	60	60	2/2/0/0/1	(12, 32)
5	Control	Acute	12w;3d/w;20min;NSG	4	65(28)	13(12)	75	50	1/0/1/1/1	(9)
6	Control	Acute	12w;3d/w;20min;IOT	5	56(27)	15(11)	40	40	1/1/2/0/1	(9)
7	RGS	Subacute	3w;5d/w;20min;	49	61(43)	70(375)	30.6	30.6	11/9/13/1/15	- (see Supplementary Material)
8	Control	Subacute	3w;5d/w;20min	4	57(17)	90(226)	0	50	4/0/0/0/0	- (see Supplementary Material)
9	RGS	Chronic	6w;5d/w;30min;+AM	9	63(31)	400(5805)	33.3	33.3	-	(1)
10	RGS	Chronic	6w;5d/w;30min	9	57(36)	735(4471)	11.1	55.6	-	(1)
11	Control	Chronic	3w;5d/w;20min;domiciliary	18	68.5(40)	751(1536)	33.3	50	6/2/4/0/6	(2, 29)
12	RGS	Chronic	3w;5d/w;20min;+OT	20	64.5(37)	770(2789)	40	30	7/0/4/0/9	(11)
13	RGS	Late Chronic	3w;5d/w;20min;domiciliary	17	61.5(43)	997(2987)	47.1	35.3	4/3/4/0/6	(2, 29)
14	RGS	Late Chronic	4w;5d/w;30min;haptics	14	63(45)	1051(3250)	50	57.1	6/0/4/1/3	(6)
15	RGS	Late Chronic	3w;5d/w;30min	15	58(60)	1261(2041)	33.3	46.7	0/1/2/0/12	(11)
16	RGS	Late Chronic	4w;5d/w;30min	16	69.5(46)	1536(3891)	43.8	62.5	6/4/5/0/1	(6)
17	RGS	Late Chronic	4w;5d/w;30min;exoskeleton	14	60(32)	1758(2880)	35.7	71.4	3/1/4/1/5	(6)

Intervention: duration of included protocols indicated per number of weeks (w), days per week (d/w), and minutes (min) of occupational therapy (OT) and VR-based therapy per day. N: sample size in the experimental group. TSO: median(maximum - minimum) days since the stroke. NSG: protocol based on non-specific gaming system (i.e., Nintendo Wii). IOT: condition including intensive occupational therapy. AM: condition including the amplification of movements in VR. Haptics: condition including delivery of haptic feedback during training. HA: percentage of patients with left hemisphere affected. Sex: percentage of males. Oxf. Class: Count of stroke types (lacunar stroke (LACS) / partial anterior circulation stroke (PACS) / total anterior circulation stroke (TACS) / or posterior circulation stroke (POCS)) according to the Oxford Stroke Classification scale. Colored rows indicate the chronicity of stroke patients participating in each study: acute (green), subacute (orange), early (blue) and late (purple) chronic stage.

105 confounding variables, recruitment for participants, intervention classification, deviations
 106 from intended interventions, missing data, measurement of outcomes and selection of
 107 reported results.

108 **Outcome Measures**

109 The primary outcome considered in this analysis was the UE motor impairment and
 110 activity at the end of therapy, as measured by two standardized clinical scales: the Fugl-
 111 Meyer Assessment of the upper extremity (UE-FM) and Chedoke Arm and Hand Activity
 112 Inventory (CAHAI)(3) scales. Previous studies have shown that the UE-FM shows excellent
 113 reliability, responsiveness and validity properties (37). Secondly, the CAHAI evaluates
 114 the UE bilateral function in the performance of specific iADLs (3). Score changes in the
 115 UE-FM and CAHAI were used as measures of motor improvement (body function and
 116 structure) and performance in iADLs respectively. In addition, the Barthel Index (16) was
 117 considered a secondary outcome for the assessment of the patient’s level of independence.

118 **Statistical Analysis**

119 We performed two analyses. Firstly, we explored recovery measures independently within
 120 each of the 17 conditions. In this analysis, we examined recovery measures using the UE-
 121 FM and CAHAI in absolute terms. Here we quantified improvement using mean differences
 122 and 95% confidence intervals (CI). Secondly, we analyzed the temporal structure of
 123 recovery post-stroke by merging all the conditions (178 patients performing RGS-based
 124 training and 368 follow-up measures) and bootstrapping our data using the Efron and Tib
 125 method (13) to evaluate the effects of the therapy across the patients’ chronicity (subacute,
 126 early chronic, and late chronic). This method overcomes the high inter-subject variability
 127 and provides a superior statistical power (13). The homogenized data was generated
 128 by separating improvement measures at different time intervals and allocating them to

129 either being an RGS-based training, OT based-training, or follow-up (i.e., no-therapy).
 130 We then calculated the improvement rate per week-normalized within-subjects according
 131 to their respective recovery potential. This metric therefore captures the improvement
 132 observed normalized to the total amount that each patient can gain given their baseline in
 133 standardized clinical scales. The normalized improvement (NI) on scale i at time t , was
 134 defined as:

$$NI(i, t) = \left(\frac{X_i(t) - X_i(t = 0)}{MaxScore_i - X_i(t = 0)} \right) * 100. \quad (1)$$

135 where $X_i(t = 0)$ refers to the corresponding baseline score. According to this nor-
 136 malization method, a patient with a baseline score of 16 in UE-FM will have 50 points
 137 of potential improvement since the UE-FM has a maximum score of 66 (9). In case this
 138 patient would recover 10 points, reaching a score of 26 points in the scale at T1, this would
 139 be equal to 20% (i.e., 10/50) of Normalized Improvement (NI). Note that this value may
 140 depend on the time lapsed between baseline measurement and subsequent assessments. We
 141 overcome this bias by dividing the NI by the number of weeks between both measurement
 142 time-points, therefore obtaining an estimate of NI per week. This normalization method
 143 allowed us to bundle the data of the different conditions while overcoming the risk of bias
 144 due to the variation in treatment intensity and response rates among protocols (26, 28, 33).
 145 We computed a NI value for three-time intervals: pre-, post-assessments, and long-term
 146 follow-up. For example, for a patient who followed RGS training with a baseline, end of
 147 the treatment, and follow-up assessment, we calculated the NI per week for two periods:
 148 baseline to end of the treatment and end of the treatment to long-term follow-up. The
 149 measured change from baseline to the end of the treatment was allocated to the RGS or the
 150 OT group, while the change from the end of the treatment to follow-up was assigned to the
 151 follow-up group. If a patient had multiple follow-up assessments at different time points,
 152 all the follow-up measures were assigned to the follow-up group.

153 For all tests, statistical significance levels were set at $p < .05$. Average and dispersion
 154 values are reported in medians \pm median absolute deviation (MAD) or means \pm standard
 155 deviation (SD) according to results from normality assessments (Kolmogorov–Smirnov
 156 normality test). To facilitate the exploration and replication of our findings, we published
 157 the complete dataset and analysis source-code as freely available and open, accessible at
 158 DOI: 10.5281/zenodo.2611949.

159 Results

160 Impact assessment of individual conditions

161 The complete dataset includes 219 stroke survivors assigned to 17 rehabilitation conditions
 162 (Table 1) at different stages post-stroke: acute (< 3 weeks), subacute (3 weeks to 6 months),
 163 early chronic (6-18 months), and late chronic (> 18 months). We observed significant gains
 164 in body function and structure after treatment, both in acute (median 20.0 ± 7.9 MAD,
 165 $p < .01$) and subacute patients (median 8.0 ± 5.6 MAD, $p < .01$), as measured by UE-
 166 FM (Figure 1 A, Table S1 in Supplementary Material [DOI: 10.5281/zenodo.2611949]).
 167 These gains were accompanied by an improved performance in iADLs in both acute
 168 (median 42.5 ± 14.1 MAD, $p < .01$) and subacute groups (median 7.0 ± 10.5 MAD, p

169 < .01)(Figure 1 B, Table S2 in Supplementary Material [DOI: 10.5281/zenodo.2611949]).
170 More interestingly, at the chronic and late chronic stage, the therapy showed overall
171 effectiveness in facilitating improvements in UE-FM (ranging from median 2.7 ± 3.8 MAD
172 to median 7.0 ± 3.6 MAD, $p < .05$) and CAHAI (median 1.0 ± 3.8 MAD to median
173 8.0 ± 5.6 MAD, $p < .05$). The application of the RGS at-home showed no significant
174 effects in UE-FM but induced statistically significant gains in the execution of iADLs
175 (median 1.0 ± 1.6 MAD, $p < .01$). Surprisingly, a dosage-matched RGS study conducted
176 in the clinic on late chronic patients had an impact on UE-FM (condition 15 in Table
177 1, median 3.0 ± 4.1 MAD, $p < .01$; Figure 1 A and B, condition Late Chronic 3w).
178 Furthermore, we observed a clear dependency between the number of days post-stroke
179 before the start of the RGS therapy and the improvements in motor function as measured
180 by UE-FM and CAHAI ($p < .001$, Spearman correlation).

181 The analysis of follow-up measures illustrates that improvements were retained in
182 all groups. The subacute group training with RGS exhibited a significant improvement
183 during the follow-up period (3 months after the end of treatment) both in UE-FM (median
184 2.0 ± 5.3 MAD, $p < .01$) and CAHAI (median 3.0 ± 11.7 MAD, $p < .01$) (Figure S3 A
185 and B in Supplementary Material [DOI: 10.5281/zenodo.2611949.]). The acute groups,
186 however, showed higher inter-individual variability and non-significant gains from the end
187 of the therapy to the follow-up.

188 **Revealing an extended critical window for recovery**

189 To study the temporal structure of recovery after stroke, we now combine the impact
190 of all the conditions and examine the effects of chronicity on the patients' normalized
191 improvement (NI, see Eq. 1 in Methods). In the group receiving therapy (RGS), we observe
192 a mean UE-FM NI per week of 5.2 ± 1.0 SD % in subacute (median 10.3 weeks), and
193 2.7 ± 0.6 SD % and 1.4 ± 0.3 SD % in early chronic (median 12.0 months) and late chronic
194 (median 3.9 years) patients respectively (Figure 2 top-left). The change on the CAHAI
195 scale shows a mean NI per week of 3.4 ± 0.7 SD % in subacute, and 1.9 ± 0.4 SD % and
196 1.1 ± 0.2 SD % in early and late chronic patients respectively (Figure 2 bottom-left). We
197 found statistically significant differences between subacute and early chronic patients, even
198 during the follow-up period ($p < .01$, Wilcoxon Rank-Sum). Those patients at the subacute
199 phase showed higher NI per week. However, only in the RGS group, the early chronic
200 group (6-18 months) showed higher recovery rates than the late chronic group (> 18
201 months) ($p < .05$, Wilcoxon Rank-Sum). This analysis reveals a long-lasting gradient of
202 sensitivity to treatment that remains visible across the first 18 months post-stroke (Figure 2
203 right). This effect was not present in the follow-up measures, a period in which no-therapy
204 was administered. Due to the low number of chronic patients in the OT group, we could
205 not apply the bootstrapping method to this sample for comparison. Despite this, we display
206 the full data to allow for visual inspection.

207 The patient's age could not explain the gradient of sensitivity to treatment found in
208 the RGS group even at early and late chronic stages (Spearman's correlation $r < 0.003$,
209 $p > .96$) and neither by the patient's baseline impairment score (Spearman's correlation
210 $r < 0.052$, $p > .43$ for FM; $r < 0.006$, $p > .93$ for CAHAI). Notice that the design
211 of this analysis controls for additional confounding variables since all patients were
212 recruited according to standard inclusion and exclusion criteria concerning age, motor

213 impairment severity, cognitive impairment severity, type of stroke (Oxford Classification),
214 hand dominance, the absence of a second stroke, and gender. None of these variables
215 correlate with the patients' chronicity, and therefore none of them can explain the uncovered
216 gradient. The homogeneity of the demographics of these patients in combination with
217 highly heterogeneous chronicity highlights the peculiarity of this data sample.

218 Finally, we analyzed the co-variation of the recovery measures of the different clinical
219 scales. We observed a distinct effect of the patient's chronicity on the association of Δ
220 UE-FM, Δ CAHAI, and Δ BI scores. While at the acute/subacute stages these recovery
221 measures correlate, they do progressively dissociate as the patient advances towards the
222 late chronic stage (Figure 3).

223 Discussion

224 In opposition to compensation, recovery of body function and structure (24) (i.e., 'true
225 recovery' according to (5)) refers to the partial or complete restoration of the repertoire of
226 behaviors that was available before injury (5, 39). In the absence of a precise assessment
227 of kinematic and kinetic measures, recovery of body function and structure has been
228 operationalized as the change in UE-FM scores (22). Previous studies on humans have
229 identified a 3-6 months period of enhanced neuroplasticity mechanisms triggered by the
230 injury (17, 19). Here, by analyzing clinical recovery scores from stroke patients with
231 variable chronicity but comparable baseline impairment levels, we are able to detect
232 a smooth decrease in the sensitivity to treatment (i.e., critical window for recovery)
233 that extends beyond 12 months post-stroke. These results suggest that there is a long-
234 lasting critical period of enhanced neuroplasticity post-stroke that enables improvement
235 in body function and structure even at late chronic stages. This is the first time that such
236 an extended critical period of recovery is reported. Capturing this effect may require
237 large homogeneous data sets and analytical methods with enhanced accuracy such as the
238 bootstrapping technique we apply here.

239 In line with the previous literature, our data illustrate the correlation of Δ UE-FM with
240 Δ CAHAI and Δ BI scores at acute stages (4, 31). However, we found that at chronic stages
241 these scales dissociate, possibly due to the introduction of compensatory mechanisms (31).
242 Altogether, our data support the interpretation of UE-FM as an assessment of recovery
243 of body function and structure that is independent of improvement in the performance of
244 iADLs and closely associated with true neurological repair (22).

245 The results presented in this study do require further investigation for a number of
246 reasons. The clinical importance of the detected improvements is marginal at late chronic
247 stages. It is relevant to notice however that the UE-FM minimal clinically important
248 difference (MCID) is derived from the chronicity-dependent variability in the UE-FM's
249 measurement error and the patient's perceived improvement thresholds (30). According to
250 previous studies, the UE-FM MCID ranges from 16 % to 30 % of the scale's maximum
251 value at acute stages (<30 days post-stroke) (23), and 7.2% to 11.0% at chronic stages (>
252 4 months post-stroke)(30). In the case of CAHAI, MCID thresholds have been established
253 above 7% of the scale range (6.3 points) for 'stable patients' within the first year post-stroke
254 (3). If the reduction of the sensitivity to treatment revealed by our analysis exists and
255 extends beyond 12 months post-stroke, these MCID estimates could be better described as

256 a continuous function of chronicity and should differentiate between late chronic and early
257 chronic patients. Future studies should explore this relationship to delineate more accurate
258 MCID thresholds.

259 It is important to note that the uncovered gradient of sensitivity to therapy may not be
260 specific to VR-based interventions. However, due to the low number of chronic patients
261 in the Occupational Therapy group, we could not perform a bootstrapping analysis in
262 this sample, and we were thus not able to evaluate the limits of the critical window
263 in these patients. Therefore, the generalization of our findings to therapies based on
264 different rehabilitation methods (e.g., Constraint-Induced Movement Therapy) needs to be
265 investigated. The factors determining the duration of this critical window and the decay
266 rate of the patient's responsiveness to treatment deserve further investigation.

267 Our results suggest that, as during ontogenesis, the re-acquisition of function after
268 stroke might have to be seen as a process that must satisfy distinct dependencies. Multiple
269 sensitive periods for the acquisition of motor and cognitive function may be structured
270 according to specific dependencies. For instance, in postnatal stages, the development of
271 neural pathways for sensory processing precedes those of language and motor functioning
272 (18). Based on our results, we speculate that the temporal structure of recovery post-stroke
273 may also comprise such a cascade of domain-specific stages or critical periods. Clinical
274 protocols for rehabilitation should be evaluated in this new context.

275 **Conclusion**

276 We have investigated the distinct dynamics of post-stroke recovery and the sensitivity
277 to treatment. By unifying results from eleven rehabilitation pilot studies, we observed
278 improvement in function over at all stages post-stroke. This effect displayed a specific
279 gradient of recovery that faded out exponentially and reached asymptotic levels after one
280 year and a half post-stroke. These findings call for an urgent scientific effort to reassess the
281 'critical window for recovery' and highlight the need for both providing early therapy and
282 extending it to patients in the chronic stages post-stroke.

283 **Funding source**

284 This study was supported by the Rehabilitation Gaming System, AAL Joint Program
285 2008-1, European Commission, the European Research Council under grant agreement
286 341196 (CDAC), EC H2020 project socSMCs (H2020EU.1.2.2. 641321) and MINECO
287 project SANAR (Gobierno de España) under agreement TIN201344200REC.

288 **Conflict of Interest Statement**

289 PV leads the research group SPECS that developed RGS, and the CEO/founder of the
290 spin-off company Eodyne Systems SL, which commercializes RGS with the goal to achieve
291 a large-scale distribution of low-cost science-based rehabilitation technologies.

292 **Author Contributions**

293 Conception and design of the study: BRB, MM, AD, MC, SB, EDO, AC, SR, RMSM,
294 and PV; implementation: BRB, MM and AD; data acquisition: BRB, MM, MC, SB;
295 analysis and interpretation: BRB, MM, AD, MC, SB, EDO, AC, SR, RMSM, and PV; and
296 manuscript preparation: BRB, MM, AD, MC, SB, EDO, AC, SR, RMSM, and PV.

297 **Funding**

298 This study was supported by the Rehabilitation Gaming System, AAL Joint Program
299 2008-1, European Commission, the European Research Council under grant agreement
300 341196 (CDAC), EC H2020 project socSMCs (H2020EU.1.2.2. 641321) and MINECO
301 project SANAR (Gobierno de España) under agreement TIN201344200REC.

302 **Acknowledgments**

303 The authors gratefully acknowledge the participation of the patients. We would like to
304 especially thank Irene Camacho, Estefanía Montiel, Leonor Vidal, and María José Aboy,
305 for their assistance in the collection of data.

306 **Data Availability Statement**

307 The complete dataset and analysis source-code is open and freely accessible at DOI:
308 10.5281/zenodo.2611949. This resource contains the following datasets:

309 **Dataset D1. [DOI: 10.5281/zenodo.2611949]** "PatientsDemographicsAndClinicalScreen-
310 ing.xlsx": Demographical data and clinical screening information (age, gender, chronicity,
311 center ID, stroke type, oxford classification, affected arm, arm dominance, presence of
312 aphasia, days after stroke).

313 **Dataset D2. [DOI: 10.5281/zenodo.2611949]** "ClinicalScalesAll.csv": Recovery
314 scores from 219 hemiparetic stroke patients evaluated using the Upper Extremity section
315 of the Fugl-Meyer, CAHAI, and BI clinical scales at multiple time points (baseline, end of
316 the treatment, and follow-up periods).

317 **References**

- 318 1. Ballester B. R., Maier M., San Segundo-Mozo R. M., Castañeda V., Duff A., and
319 Verschure P F M J. Counteracting learned non-use in chronic stroke patients with
320 reinforcement-induced movement therapy. *Journal of NeuroEngineering and Rehabil-*
321 *itation*, 13(1):74, 2016.
- 322 2. Ballester B.R., Nirme J., Camacho C., Duarte E., Rodriguez S., Cuxart A., Duff A.
323 and Verschure, PFMJ. Domiciliary VR-Based Therapy for Functional Recovery and
324 Cortical Reorganization : Randomized Controlled Trial in Participants at the Chronic
325 Stage Post Stroke. *JMIR*, 5(3):1–12, 2017. doi: 10.2196/games.6773.
- 326 3. Barreca SR., Stratford PW., Lambert CL., Masters LM., and Streiner DL. Test-Retest
327 reliability, validity, and sensitivity of the chedoke arm and hand activity inventory:
328 A new measure of upper-limb function for survivors of stroke. *Archives of Physical*

- 329 *Medicine and Rehabilitation*, 86(8):1616–1622, 2005. ISSN 00039993. doi: 10.1016/
330 j.apmr.2005.03.017.
- 331 4. Beebe JA. and Lang CE. Relationships and responsiveness of six upper extremity
332 function tests during the first 6 months of recovery after stroke. *Journal of neurologic*
333 *physical therapy: JNPT*, 33(2):96, 2009.
- 334 5. Bernhardt J., Hayward K.S., Kwakkel G., Ward NS., Wolf SL., Borschmann K.,
335 Krakauer JW., Boyd LA., Carmichael ST., Corbett D., and Cramer SC. Agreed
336 definitions and a shared vision for new standards in stroke recovery research: the
337 stroke recovery and rehabilitation roundtable taskforce. *International Journal of*
338 *Stroke*, 12(5):444–450, 2017.
- 339 6. Cameirão M. S. , Badia S. B., Duarte E., Frisoli A., and Verschure PFMJ. The
340 Combined Impact of Virtual Reality Neurorehabilitation and Its Interfaces on Upper
341 Extremity Functional Recovery in Patients With Chronic Stroke. *Stroke*, 43(10):2720–
342 2728, oct 2012. ISSN 0039-2499. doi: 10.1161/STROKEAHA.112.653196. URL
343 <http://stroke.ahajournals.org/cgi/doi/10.1161/STROKEAHA.112.653196>.
- 344 7. Cameirão MS., Bermudez i Badia S., Duarte Oller E., and Verschure P.F.M.J. Neu-
345 rorehabilitation using the virtual reality based Rehabilitation Gaming System: method-
346 ology, design, psychometrics, usability and validation. *Journal of NeuroEngineering*
347 *and Rehabilitation*, 7(1):48, 2010. ISSN 1743-0003. doi: 10.1186/1743-0003-7-48.
348 URL <http://www.jneuroengrehab.com/content/7/1/48>.
- 349 8. Corbetta M., Ramsey L., Callejas A., Baldassarre A., Hacker C.D., Siegel J.S., Astafiev
350 S.V., Rengachary J., Zinn C., Lang C.E., et al. Common behavioral clusters and
351 subcortical anatomy in stroke. *Neuron*, 85(5):927–941, 2015.
- 352 9. Silva Cameirão M., Bermúdez i Badia S., Duarte E., and Verschure P.F.M.J. Virtual
353 reality based rehabilitation speeds up functional recovery of the upper
354 extremities after stroke: a randomized controlled pilot study in the acute phase
355 of stroke using the rehabilitation gaming system. *Restorative Neurology And*
356 *Neuroscience*, 29(5):287–298, 2011. ISSN 09226028. doi: 10.3233/RNN-2011-0599.
357 URL <http://search.ebscohost.com.lib.fontys.nl/login.aspx?direct=true{%&}db=mnh{%&}AN=21697589{%&}site=ehost-live{%&}scope=site{%&}5Cnhttp://content.iospress.com/download/restorative-neurology-and-neuroscience/rnn599?id=restorative-neurology-and-neuroscience/rnn599>
- 361 10. Dromerick A.W., Edwardson M.A., Edwards D.F., Giannetti M.L., Barth J., Brady
362 K.P., Chan E., Tan M.T., Tamboli I., Chia R., Orquiza M., Padilla R.M., Cheema
363 A.K., Mapstone M.E., Fiandaca M.E., Federoff H.J., and Newport E.L. Critical
364 periods after stroke study: translating animal stroke recovery experiments into a
365 clinical trial. *Frontiers in Human Neuroscience*, 9, 2015. ISSN 1662-5161. doi:
366 10.3389/fnhum.2015.00231. URL <http://journal.frontiersin.org/article/10.3389/fnhum.2015.00231/abstract>.
- 368 11. Duff A., Duarte E., Cuxart A., Rodr'iguez S., Cameirão M., Bermúdez i Badia S,
369 and Verschure P.F.M.J. Rehabilitation Gaming System (rgs): The Impact Of Virtual

- 370 Reality Based Training On Upper Limb Recovery In The Acute And Chronic Phase
371 Of Stroke. *Cerebrovascular Diseases*, 31:190, 2011.
- 372 12. Duff A., Nirme J., Ballester B.R., Duarte E., Cuxart A., Rodriguez S., and Verschure
373 P.F.M.J. The optimal dosage of the Rehabilitation Gaming System: The impact of a
374 longer period of virtual reality based and standard occupational training on upper limb
375 recovery in the acute phase of stroke. In *Cerebrovascular Diseases*, volume 35, page
376 146, 2013.
- 377 13. Efron B. and Tibshirani R. Bootstrap methods for standard errors, confidence intervals,
378 and other measures of statistical accuracy. *Statistical science*, pages 54–75, 1986.
- 379 14. Eilers P.H.C. A perfect smoother. *Analytical chemistry*, 75(14):3631–3636, 2003.
- 380 15. Feigin V.L., Forouzanfar M.H., Krishnamurthi R., Mensah G., Connor M., Bennett D.,
381 Moran A.E., Sacco R.L., Anderson L., Truelsen T., O'Donnell M., Venketasubrama-
382 nian N., Barker-Collo S., Lawes C.M.M., Wang W., Shinohara Y., Witt E., Ezzati M.,
383 and Naghavi M.. Global and regional burden of stroke during 1990-2010: Findings
384 from the Global Burden of Disease Study 2010. *The Lancet*, 383(9913):245–255,
385 2014. ISSN 01406736. doi: 10.1016/S0140-6736(13)61953-4.
- 386 16. Granger C.V., Albrecht G.L., and Hamilton B.B.. Outcome of comprehensive medical
387 rehabilitation: measurement by PULSES profile and the Barthel Index. *Archives of*
388 *physical medicine and rehabilitation*, 60(4):145–154, 1979.
- 389 17. Hendricks H.T., van Limbeek J., Geurts A.C., and Zwarts M.J. Motor recovery after
390 stroke: a systematic review of the literature. *Archives of physical medicine and*
391 *rehabilitation*, 83(11):1629–1637, 2002.
- 392 18. Hensch T.K. Critical period plasticity in local cortical circuits. *Nature Reviews*
393 *Neuroscience*, 6(11):877, 2005.
- 394 19. Kitago T. and Krakauer J.W. Motor learning principles for neurorehabilitation. In
395 *Handbook of clinical neurology*, volume 110, pages 93–103. Elsevier, 2013.
- 396 20. Krakauer J.W. and Cort J.C. A non-task-oriented approach based on high-dose playful
397 movement exploration for rehabilitation of the upper limb early after stroke : A
398 proposal. 43:31–40, 2018. doi: 10.3233/NRE-172411.
- 399 21. Kwakkel G., Kollen B., and Lindeman E. Understanding the pattern of functional
400 recovery after stroke: facts and theories. *Restorative Neurology and Neuroscience*, 22
401 (3-5):281–299, 2004. ISSN 0922-6028. doi: 10.1177/1545968308317972.
- 402 22. Kwakkel G., Lannin N.A., Borschmann K., English C., Ali M., Churilov L., Saposnik
403 G., Winstein C., Van Wegen E.E.H., Wolf S.L., Krakauer J.W., and Bernhardt J.
404 Standardized measurement of sensorimotor recovery in stroke trials : Consensus-
405 based core recommendations from the Stroke Recovery and Rehabilitation Roundtable.
406 12(5):451–461, 2017. doi: 10.1177/1747493017711813.

- 407 23. Lang C.E., Edwards D.F., Birkenmeier R.L., and Dromerick A.W. Estimating mini-
408 mal clinically important differences of upper-extremity measures early after stroke.
409 *Archives of physical medicine and rehabilitation*, 89(9):1693–1700, 2008.
- 410 24. Levin M.F., Kleim J.A., and Wolf S.L. What do motor “recovery” and “compensation”
411 mean in patients following stroke? *Neurorehabilitation and neural repair*, 23(4):
412 313–319, 2009.
- 413 25. Maier M., Ballester B.R., Duff A., Duarte-Oller E., and Verschure P.F.M.J. Effect of
414 Specific Over Nonspecific VR-Based Rehabilitation on Poststroke Motor Recovery:
415 A Systematic Meta-analysis. *Neurorehabilitation and neural repair*, 3(2): 112-129,
416 2019.
- 417 26. Makuch R.W. and Johnson M.F. Dilemmas in the use of active control groups in
418 clinical research. *IRB: Ethics & Human Research*, 11(1):1–5, 1989.
- 419 27. McDonnell M.N., Koblar S., Ward N.S., Rothwell J.C., Hordacre B., and Ridding
420 M.C. An investigation of cortical neuroplasticity following stroke in adults: is there
421 evidence for a critical window for rehabilitation? *BMC neurology*, 15(1):109, 2015.
- 422 28. Medica E.M., Laver K., George S., Thomas S., and Deutsch J.E. Virtual reality for
423 stroke rehabilitation : an abridged version of a Cochrane Review Eur J Phys Rehabil
424 Med 2015 Jul 09 [Epub ahead of print] EUROPEAN JOURNAL OF PHYSICAL
425 AND REHABILITATION COPYRIGHT © 2015 EDIZIONI MINERVA MEDICA
426 Virtual reality for st. *European Journal of Physical and Rehabilitation Medicine*, Jul
427 09 [Ep:CD008349, jan 2015. ISSN 1469-493X. doi: 10.1002/14651858.CD008349.
428 pub3.]. URL <http://www.ncbi.nlm.nih.gov/pubmed/25927099>.
- 429 29. Nirme J., Ballester B.R., Duff A., Duarte E., Rodriguez S., Cuxart A., and Verschure
430 P.F.M.J. At Home Motor Rehabilitation in the Chronic Phase of Stroke Using the
431 Rehabilitation Gaming System. In *Converging clinical and engineering research on
432 neurorehabilitation*, pages 931–935. Springer, Berlin, Heidelberg, 2013.
- 433 30. Page S.J., Fulk J.D., and Boyne P. Clinically important differences for the upper-
434 extremity Fugl-Meyer Scale in people with minimal to moderate impairment due to
435 chronic stroke. *Physical therapy*, 92(6):791–798, 2012.
- 436 31. Rabadi M.H. and Rabadi F.M. Comparison of the action research arm test and the
437 Fugl-Meyer assessment as measures of upper-extremity motor weakness after stroke.
438 *Archives of physical medicine and rehabilitation*, 87(7):962–966, 2006.
- 439 32. Rodriguez S., Bermúdez i Badia S., Cameirão M., Cuxart-Fina A., Duarte E., Duff
440 A., and Verschure P.F.M.J. Session 225 Effects of Virtual Reality Upper Limb Based
441 Training (Rehabilitation Gaming System) on Spasticity, Shoulder Pain, and Depression
442 After Stroke. *PM&R*, 3(10):S160, 2011.
- 443 33. Saposnik G. and Levin M. Virtual Reality in Stroke Rehabilitation: A Meta-Analysis
444 and Implications for Clinicians. *Stroke*, 42(5):1380–1386, may 2011. ISSN 0039-2499.
445 doi: 10.1161/STROKEAHA.110.605451. URL [http://stroke.ahajournals.org/cgi/doi/
446 10.1161/STROKEAHA.110.605451](http://stroke.ahajournals.org/cgi/doi/10.1161/STROKEAHA.110.605451).

- 447 34. Teasell R.W., Foley N.C., Bhogal S.K., and Speechley M.R. An evidence-based review
448 of stroke rehabilitation. *Topics in stroke Rehabilitation*, 2015.
- 449 35. Veerbeek J.M., van Wegen E., van Peppen R., van der Wees P.J., Hendriks E., Rietberg
450 M., and Kwakkel G. What Is the Evidence for Physical Therapy Poststroke? A
451 Systematic Review and Meta-Analysis. *PLoS ONE*, 9(2):e87987, 2014. ISSN 1932-
452 6203. doi: 10.1371/journal.pone.0087987. URL <http://dx.plos.org/10.1371/journal.pone.0087987>.
- 454 36. Ward N.S. Restoring brain function after. *Nature Publishing Group*, 2017. ISSN
455 1759-4758. doi: 10.1038/nrneurol.2017.34. URL <http://dx.doi.org/10.1038/nrneurol.2017.34>.
- 457 37. Wei X.J., Tong K.Y., and Hu X.L. The responsiveness and correlation between Fugl-
458 Meyer Assessment, Motor Status Scale, and the Action Research Arm Test in chronic
459 stroke with upper-extremity rehabilitation robotic training. *International journal of
460 rehabilitation research. Internationale Zeitschrift für Rehabilitationsforschung. Revue
461 internationale de recherches de réadaptation*, 34(4):349–56, 2011. ISSN 1473-5660.
462 doi: 10.1097/MRR.0b013e32834d330a. URL <http://www.ncbi.nlm.nih.gov/pubmed/22044987>.
- 464 38. WHO. *International classification of functioning, disability and health: ICF*. Geneva:
465 World Health Organization, 2001.
- 466 39. Zeiler S.R. and Krakauer J.W. The interaction between training and plasticity in the
467 post-stroke brain. *Current opinion in neurology*, 26(6):609, 2013.
- 468 40. Zeiler S.R., Hubbard R., Gibson E.M., Zheng T., Ng K., O'Brien K., and Krakauer
469 J.W. Paradoxical motor recovery from a first stroke after induction of a second stroke:
470 reopening a postischemic sensitive period. *Neurorehabilitation and neural repair*, 30
471 (8):794–800, 2016.

Figure 1





Figure 2

A The effects of therapy by chronicity



B Recovery across chronicity




Figure 3

